Systemic Therapy for Metastatic Colorectal Cancer
Sequencing therapy in the metastatic setting is challenging and requires that clinicians consider overlapping mechanisms of action and toxicity profiles when selecting among agents. Clinicians need to be aware of the new data, new FDA approvals, and new changes in the guideline recommendations for metastatic colorectal cancer in order to choose appropriate systemic therapies, which is critical to ensure optimal treatment of patients.
This educational activity is designed to meet the needs of physicians, nurses, pharmacists, and other clinical professionals who manage patients with cancer.
Following this activity, participants should be able to:
- Discuss new data on metastatic colorectal cancer, particularly as it relates to the NCCN Guidelines for Colon and Rectal Cancer
Leonard Saltz, MD
Memorial Sloan-Kettering Cancer Center
- 0.25 Participation
- 0.33 Nurse
- 0.25 Pharmacist
- 0.25 Physician